U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054359) titled '"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"' on Jan. 09.
Brief Summary: To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral prophylaxis (PAP) by tenofovir. Current international guidelines require hepatitis B surface antigen (HBsAg)-positive pregnant women to undergo viral load (VL) quantification to identify those at high risk (VL >=200,000 IU/mL) who should receive PAP. However, VL testing remains inaccessibl...